A recent study suggests that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight far faster than those who stop traditional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while obese people often shed substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such drugs must be cognizant of the danger of fast rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about one and a half years.
Comparing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.
The team point out that individuals who lose weight through diet and exercise generally experience a more gradual creep back—around 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists suggest the way of the jabs explains the heightened regain.
These medications copy a body's own chemical called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is no longer kept in check, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals argue that, due to the significant potential of weight regain, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who state that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Experiences
Users who have discontinued the jabs explain a powerful resurgence of hunger.
"I experienced a switch activating and you become starving," described a patient.
This difficulty is worsened if individuals have not established sustainable dietary or behavioural modifications during therapy.
Significant Use
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated lifestyle support.
